Portfolio Design Labs LLC acquired a new stake in Danaher Corporation (NYSE:DHR – Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 6,796 shares of the conglomerate’s stock, valued at approximately $1,295,000.
Other hedge funds have also modified their holdings of the company. BlackRock Inc. bought a new position in shares of Danaher during the 2nd quarter worth approximately $10,492,520,000. Norges Bank acquired a new position in shares of Danaher during the 4th quarter worth about $2,177,106,000. Generation Investment Management LLP acquired a new position in Danaher during the second quarter worth approximately $1,287,949,000. Flossbach Von Storch SE acquired a new position in shares of Danaher during the 2nd quarter worth approximately $747,260,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Danaher in the second quarter valued at about $712,875,000. 79.05% of the stock is currently owned by institutional investors.
Danaher Trading Up 2.2%
Shares of DHR opened at $216.14 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80. The firm has a market cap of $151.94 billion, a price-to-earnings ratio of 38.39, a PEG ratio of 2.63 and a beta of 0.78. The business’s fifty day moving average is $195.01 and its 200-day moving average is $192.43.
Analysts Set New Price Targets
DHR has been the topic of several research reports. Argus decreased their target price on Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a research report on Friday, April 24th. TD Cowen lowered their price objective on Danaher from $240.00 to $236.00 and set a “buy” rating on the stock in a research report on Wednesday, July 22nd. HSBC dropped their target price on Danaher from $270.00 to $230.00 and set a “buy” rating for the company in a report on Wednesday, June 3rd. Guggenheim reduced their target price on shares of Danaher from $235.00 to $200.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. Finally, Wolfe Research downgraded shares of Danaher from an “outperform” rating to a “peer perform” rating in a research note on Monday, June 1st. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and a consensus target price of $228.91.
Check Out Our Latest Research Report on DHR
Danaher Company Profile
Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.
Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.
See Also
- Five stocks we like better than Danaher
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
